Proton Therapy: A Path to Improved Outcomes and Quality of Life
Although development outlays with proton therapy have decreased, treatment costs remain higher than for conventional radiotherapy, fueling a debate about whether the benefits justify the costs.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512